TGFB1 and neoplasm: Accordingly, treatment with dual monoclonal antibody strategy with the capacity to inhibit TGFβ and PD-1/PD-L1 has resulted more effective than treatment with either PD-L1 antibody or TGFβ trap alone in increased T cells, NK cells, and decreased neutrophils and myeloid-derived suppressor in tumor-derived cells from syngeneic mouse model (52).